(ELAN) Elanco Animal Health - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NYSE (USA) | Market Cap: 10.808m USD | Total Return: 50.8% in 12m
Parasiticides, Vaccines, Antibiotics, Feed Additives, Therapeutics
Total Rating 56
Safety 59
Buy Signal 0.34
Drug Manufacturers - Specialty & Generic
Industry Rotation: -7.5
Industry Rotation: -7.5
Market Cap:
10.8B
Avg Turnover: 138M
Avg Turnover: 138M
Risk 3d forecast
Volatility72.0%
VaR 5th Pctl10.6%
VaR vs Median-12.7%
Reward TTM
Sharpe Ratio1.13
Rel. Str. IBD42.1
Rel. Str. Peer Group44.8
Character TTM
Beta1.510
Beta Downside1.272
Hurst Exponent0.361
Drawdowns 3y
Max DD56.10%
CAGR/Max DD0.56
CAGR/Mean DD2.03
EPS (Earnings per Share)
EPS CAGR: 2.85%
EPS Trend: -5.5%
EPS Trend: -5.5%
Last SUE: 1.49
Qual. Beats: 1
Qual. Beats: 1
Revenue
Rev. CAGR: 4.20%
Rev. Trend: 43.1%
Rev. Trend: 43.1%
Last SUE: 4.00
Qual. Beats: 5
Qual. Beats: 5
Warnings
Interest Coverage Ratio -0.3 is critical
Altman Z'' 0.02 < 1.0 - financial distress zone
Tailwinds
Pead
Description: ELAN Elanco Animal Health
Elanco Animal Health (ELAN) is a global provider of health products for pets and livestock, operating in the animal health sector-an industry characterized by high barriers to entry due to stringent regulatory requirements and long R&D cycles. The company’s portfolio includes parasiticides, vaccines, and therapeutics marketed under brands such as Seresto, Credelio, and Galliprant. For the farm animal segment, Elanco produces medicated feed additives and antibiotics designed to improve livestock productivity and welfare.
The business model relies on a multi-channel distribution strategy, selling through third-party distributors, independent retailers, and directly to veterinarians and agricultural producers. Unlike human pharmaceuticals, animal health companies often benefit from lower generic competition and more direct-to-consumer brand loyalty in the pet segment. Investors can evaluate the company’s valuation metrics and growth trajectory further on ValueRay.
Headquartered in Indianapolis and founded in 1954, Elanco maintains a global footprint with diversified revenue streams across species and geographic regions. The company focuses on product innovation to address chronic conditions in pets and efficiency challenges in the global food supply chain.
- New blockbuster product launches drive high-margin revenue growth in pet therapeutics
- Innovation pipeline execution determines long-term competitiveness against established animal health peers
- Input cost fluctuations and manufacturing efficiencies impact consolidated EBITDA margins
- Global livestock demand and protein consumption patterns dictate farm animal segment performance
- High debt leverage and interest expense levels constrain free cash flow allocation options
Piotroski VR‑10 (Strict)
4.0
| Net Income: -242.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.25 > 1.0 |
| NWC/Revenue: 39.28% < 20% (prev 49.04%; Δ -9.76% < -1%) |
| CFO/TA 0.04 > 3% & CFO 577.0m > Net Income -242.0m |
| Net Debt (3.56b) to EBITDA (755.0m): 4.72 < 3 |
| Current Ratio: 2.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (506.0m) vs 12m ago 1.38% < -2% |
| Gross Margin: 49.44% > 18% (prev 0.43%; Δ 4.90k% > 0.5%) |
| Asset Turnover: 37.40% > 50% (prev 34.21%; Δ 3.19% > 0%) |
| Interest Coverage Ratio: -0.26 > 6 (EBITDA TTM 755.0m / Interest Expense TTM 270.0m) |
Altman Z''
0.02
| A: 0.15 (Total Current Assets 3.58b - Total Current Liabilities 1.66b) / Total Assets 13.22b |
| B: -0.16 (Retained Earnings -2.12b / Total Assets 13.22b) |
| C: -0.01 (EBIT TTM -71.0m / Avg Total Assets 13.08b) |
| D: -0.35 (Book Value of Equity -2.36b / Total Liabilities 6.72b) |
| Altman-Z'' Score: 0.02 = B |
Beneish M
-3.17
| DSRI: 0.98 (Receivables 1.15b/1.06b, Revenue 4.89b/4.43b) |
| GMI: 0.87 (GM 49.44% / 43.10%) |
| AQI: 0.95 (AQ_t 0.62 / AQ_t-1 0.65) |
| SGI: 1.11 (Revenue 4.89b / 4.43b) |
| TATA: -0.06 (NI -242.0m - CFO 577.0m) / TA 13.22b) |
| Beneish M-Score: -3.17 (Cap -4..+1) = AA |
What is the price of ELAN shares?
As of May 19, 2026, the stock is trading at USD 19.93 with a total of 6,769,755 shares traded.
Over the past week, the price has changed by -8.24%, over one month by -15.84%, over three months by -19.57% and over the past year by +50.76%.
Over the past week, the price has changed by -8.24%, over one month by -15.84%, over three months by -19.57% and over the past year by +50.76%.
Is ELAN a buy, sell or hold?
Elanco Animal Health has received a consensus analysts rating of 3.87.
Therefore, it is recommended to buy ELAN.
- StrongBuy: 6
- Buy: 1
- Hold: 8
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ELAN price?
| Analysts Target Price | 29.9 | 49.8% |
Elanco Animal Health (ELAN) - Fundamental Data Overview
as of 16 May 2026
P/E Forward = 18.9036 P/S = 2.2089
P/B = 1.8172
P/EG = 4.0421
Revenue TTM = 4.89b USD
EBIT TTM = -71.0m USD
EBITDA TTM = 755.0m USD
Long Term Debt = 3.92b USD (from longTermDebt, last quarter)
Short Term Debt = 73.0m USD (from shortTermDebt, last quarter)
Debt = 3.99b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.56b USD (from netDebt column, last quarter)
Enterprise Value = 14.37b USD (10.81b + Debt 3.99b - CCE 428.0m)
Interest Coverage Ratio = -0.26 (Ebit TTM -71.0m / Interest Expense TTM 270.0m)
EV/FCF = 45.62x (Enterprise Value 14.37b / FCF TTM 315.0m)
FCF Yield = 2.19% (FCF TTM 315.0m / Enterprise Value 14.37b)
FCF Margin = 6.44% (FCF TTM 315.0m / Revenue TTM 4.89b)
Net Margin = -4.95% (Net Income TTM -242.0m / Revenue TTM 4.89b)
Gross Margin = 49.44% ((Revenue TTM 4.89b - Cost of Revenue TTM 2.47b) / Revenue TTM)
Gross Margin QoQ = 57.26% (prev 39.34%)
Tobins Q-Ratio = 1.09 (Enterprise Value 14.37b / Total Assets 13.22b)
Interest Expense / Debt = 1.43% (Interest Expense 57.0m / Debt 3.99b)
Taxrate = 34.48% (30.0m / 87.0m)
NOPAT = -46.5m (EBIT -71.0m * (1 - 34.48%)) [loss with tax shield]
Current Ratio = 2.16 (Total Current Assets 3.58b / Total Current Liabilities 1.66b)
Debt / Equity = 0.61 (Debt 3.99b / totalStockholderEquity, last quarter 6.50b)
Debt / EBITDA = 4.72 (Net Debt 3.56b / EBITDA 755.0m)
Debt / FCF = 11.31 (Net Debt 3.56b / FCF TTM 315.0m)
Total Stockholder Equity = 6.64b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.85% (Net Income -242.0m / Total Assets 13.22b)
RoE = -3.64% (Net Income TTM -242.0m / Total Stockholder Equity 6.64b)
RoCE = -0.67% (EBIT -71.0m / Capital Employed (Equity 6.64b + L.T.Debt 3.92b))
RoIC = -0.43% (negative operating profit) (NOPAT -46.5m / Invested Capital 10.70b)
WACC = 8.50% (E(10.81b)/V(14.80b) * Re(11.29%) + D(3.99b)/V(14.80b) * Rd(1.43%) * (1-Tc(0.34)))
Discount Rate = 11.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 60.0 | Cagr: 1.18%
[DCF] Terminal Value 73.22% ; FCFF base≈325.4m ; Y1≈266.9m ; Y5≈190.5m
[DCF] Fair Price = N/A (negative equity: EV 3.24b - Net Debt 3.56b = -321.7m; debt exceeds intrinsic value)
EPS Correlation: -5.48 | EPS CAGR: 2.85% | SUE: 1.49 | # QB: 1
Revenue Correlation: 43.13 | Revenue CAGR: 4.20% | SUE: 4.0 | # QB: 5
EPS current Quarter (2026-06-30): EPS=0.27 | Chg30d=-6.78% | Revisions=-50% | Analysts=11
EPS next Quarter (2026-09-30): EPS=0.20 | Chg30d=+0.77% | Revisions=-25% | Analysts=10
EPS current Year (2026-12-31): EPS=1.09 | Chg30d=+4.25% | Revisions=+57% | GrowthEPS=+15.6% | GrowthRev=+7.0%
EPS next Year (2027-12-31): EPS=1.21 | Chg30d=+3.71% | Revisions=+54% | GrowthEPS=+11.7% | GrowthRev=+5.3%
[Analyst] Revisions Ratio: +57%